Copy number variations (CNVs) have recently drawn attention as an important genetic factor for diseases, especially common neuropsychiatric disorders including Alzheimer's disease (AD). Because most of the pathogenic CNV regions overlap with multiple genes, it has been challenging to identify the true disease-causing genes amongst them. Notably, a recent study reported that CNV regions containing ohnologs, which are dosage-sensitive genes, are likely to be deleterious. Utilizing the unique feature of ohnologs could be useful for identifying causative genes with pathogenic CNVs, however its effectiveness is still unclear. Although it has been reported that AD is strongly affected by CNVs, most of ADcausing genes with pathogenic CNVs have not been identified yet. Here, we show that dosage-sensitive ohnologs within CNV regions reported in patients with AD are related to the nervous system and are highly expressed in the brain, similar to other known susceptible genes for AD. We found that CNV regions in patients with AD contained dosage-sensitive genes, which are ohnologs not overlapping with control CNV regions, frequently. Furthermore, these dosage-sensitive genes in pathogenic CNV regions had a strong enrichment in the nervous system for mouse knockout phenotype and high expression in the brain similar to the known susceptible genes for AD. Our results demonstrated that selecting dosage-sensitive ohnologs out of multiple genes with pathogenic CNVs is effective in identifying the causative genes for AD. This methodology can be applied to other diseases caused by dosage imbalance and might help to establish the medical diagnosis by analysis of CNVs.
Introduction
Copy number variations (CNVs) have recently attracted attention as the common factor of genetic variation ). CNVs are categorized into deletions or duplications that are >1 kb of the genome (Feuk et al. 2006) . They comprise common polymorphic variants and rare mutations, which are inherited or occur de novo. Because CNV regions often include a gene or many genes and involve a change in their copy numbers, CNVs leads to gene expression and phenotypic variability (Walsh et al. 2008; Gamazon and Stranger 2015) . Thus, it has been suggested that some rare CNVs overlapping with genes can be deleterious resulting in diseases; a previous report showed that pathogenic CNVs are under strong selection pressure (Rees et al. 2011 ). Thus, CNVs may extend our understanding of the genetic basis of diseases.
Many reports on the associations between CNVs and diseases have suggested the importance of their roles as genetic factors of pathogenesis, especially in common and complex disorders with psychological symptoms (Malhotra and Sebat 2012) , including autism spectrum disorders, schizophrenia, epilepsy, and intellectual disability (Mefford et al. 2010; Marangi et al. 2013; Szatkiewicz et al. 2014; Oikonomakis et al. 2016) . For example, deletions of NRXN1 (neurexin 1) associate with these neurodevelopmental disorders (Rujescu et al. 2009; Zweier et al. 2009 ). Deletions in 6p22.3-p24.3 containing >30 genes is a risk factor for autism spectrum disorders and developmental delay (CelestinoSoper et al. 2012) . Although some candidate genes are suggested in the research based on previous articles reporting the noxious effects of each gene, it is not efficient to identify a true disease-causing gene within CNV regions because most of the genes with pathogenic CNVs would be unrelated to the disease.
For identifying the disease-causing genes within CNV regions, we can take advantage of the fact that CNVs of dosage-sensitive genes, which are vulnerable to gene copy number changes, are deleterious. Importantly, CNVs are not randomly distributed in the human genome and are unlikely to overlap with "ohnologs" (Makino and McLysaght 2010; Makino et al. 2013; McLysaght et al. 2014) . Ohnologs are duplicated genes derived from whole genome duplications and are dosage-sensitive and frequently associate with diseases (Makino and McLysaght 2010) . Notably, it has also been shown that ohnologs are refractory to CNVs owing to their dosage sensitivities. Thus, the unique characteristics of ohnologs could be applied to estimate the deleterious and pathogenic genes efficiently out of many genes within the reported CNV regions in patients.
Particularly, it has been reported that ohnologs significantly overlap with CNV regions, which were observed in patients with five major neurodevelopmental disorders (McLysaght et al. 2014 ). This result demonstrated that CNV regions overlapping with ohnologs are deleterious and suggested that ohnologs are responsible for the deleterious phenotype and that dosage sensitivity is associated with psychological symptoms. Moreover, it has been proposed that focusing on ohnologs among the genes overlapping with pathogenic CNV regions may be helpful for diagnosis in the future (McLysaght et al. 2014 ).
Alzheimer's disease (AD) is a neurodegenerative disease with various neuropsychological features caused by malfunction of neuron-to-neuron communication at the synapses and loss of neurons in the brain (Alzheimer's Association 2013). It is known that genetic factors play a key role; however, the established AD genes-APP (amyloid precursor protein), PSEN1 and PSEN2 (presenilin 1 and 2), and APOE (apolipoprotein E) e4 allele do not account for all of the causes of AD (Gatz et al. 2006) . Although many genomewide studies on CNVs related to AD have been reported recently, the causative gene with pathogenic CNVs has not been identified yet, when many genes were included in CNV regions.
The reason why we gained interest in AD is that it could be associated with dosage sensitivity. APP is an ohnolog and also one of the causative genes of Down Syndrome (trisomy 21) caused by 1.5-fold dosage, whose patients often experience AD (Makino and McLysaght 2010) . Some studies have reported that duplications of APP are a substantial cause for familial AD (Rovelet-Lecrux et al. 2006; Sleegers et al. 2006; McNaughton et al. 2012 ) and associate with sporadic AD (Bushman et al. 2015) Remarkably, deletion of APP via partial trisomy cause AD-protective effects in Down Syndrome (Prasher et al. 1998) . These reports showed that APP is a dosage-sensitive ohnolog, resulting in a strong causative gene for AD when its gene dosage changes. There are some other candidates for dosage-sensitive genes susceptible for AD such as ATXN1, which was found in the deletions of 6p22.3-p24.3 and its CNV regions associated with neurological abnormalities (Celestino-Soper et al. 2012) . Thus, the destruction of gene dose balance might be a key factor in AD pathogenesis. The purpose of this study was to investigate whether dosage sensitivity is a factor in AD pathogenesis by examining the enrichment of ohnologs within AD CNV regions and their CNVs in human populations. Furthermore, we validated the causative candidate genes by investigating their mouse knockout phenotypes and expression levels in the brain.
Results

Dosage-Sensitive Genes within AD CNV Regions
We obtained 61 AD CNV regions that contained at least 1 protein-coding gene and 497 protein-coding genes within these regions, defined as "AD CNV genes," from previously reported genome-wide studies for CNVs in patients with AD/ Mild Cognitive Impairment (MCI) (supplementary table S1, Supplementary Material online). To investigate whether dosage sensitivity plays a role in AD pathogenesis, we estimated the proportion of CNV regions containing an ohnolog in 61 AD CNV regions. The proportion was 50 out of 61 CNV regions (82%) in AD CNV regions, while 8,724 out of 24,034 CNVs (36%) in control CNVs from Database of genomic variants (DGV; table 1), which were significantly different (P ¼ 3:54Â10 À13 ; v 2 test). However, the size of control CNV regions tended to be smaller than that of AD CNV regions; thus, it was less likely to contain an ohnolog because of overlapping of fewer genes. The mean number of genes in 1 control CNV region and AD CNV region were 2.70 and 8.18, respectively. To overcome this issue, we classified CNV regions into five groups with the different number of genes in them and analyzed them in the same way. We found that AD CNV regions had a higher tendency of containing an ohnolog compared with control CNV regions for all five groups, containing only 1, 2-5, 6-10, 11-20, and >20 genes within a single CNV region (table 1) . Specifically, for CNV regions with only 1, 2-5, and 6-10 genes, there were significant differences in the proportion of CNV regions containing an ohnolog between genes in AD CNV regions and control CNV regions (CNV regions with only 1 gene; AD CNV regions; 60%, 12 out of 20; control CNV regions; 26%, 3,208 out of 12,574; P ¼ 0:0026; fisher 0 s exact test; CNV regions with 2-5 genes; AD CNV regions; 94%, 17 out of 18; control CNV regions; 37%, 3,902 out of 9,094; P ¼ 3:09Â10 À5 ; fisher 0 s exact test; CNVs with 6-10 genes; AD CNV regions; 86%, 6 out of 7; control CNV regions; 63%, 1,029 out of 1,636; P ¼ 0:0026; fisher 0 s exact test). However, there were no significant differences in the rest of the larger groups (table 1). The genes within one-gene AD CNV regions might be causative for AD because each CNV region contained only 1 gene. This result suggested that AD CNVs would disturb the dose of dosage-sensitive genes such as ohnologs, and thus, contribute to the pathogenesis of AD. We also examined the proportion of genes without any control CNVs, which were defined as "nonCNV genes," in 20 onegene AD CNV regions. Nine out of 20 genes (45%) in the AD CNV regions were nonCNV genes while only 5,640 out of 19,895 in the other human genes (28%). Although there was no significant difference in the proportions of nonCNV genes because of the small gene set (P ¼ 0:13; fisher 0 s exact test), these results suggested that the disruption of gene dosage balance is a key factor in AD pathogenesis. In addition, we examined a difference in the degree of CNVs containing an ohnolog between AD CNVs and control CNVs in human populations. For investigating the degree of CNVs, we used CNVs having at least one gene for 67,274 individuals as reported in the DGV database. We found that the degree of CNVs containing an ohnolog included in AD CNVs (average: 2.2 individuals per CNV) was significantly lower than that of other control CNVs containing an ohnolog (average: 9.5 individuals per CNV; P ¼ 0.0021, Mann-Whitney U test). Note that the degree of control CNVs containing an ohnolog was significantly lower than that of control CNVs containing a nonohnolog (average: 18.1 individuals per CNV; P < 2.2 Â 10
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, Mann-Whitney U test). This indicates that ohnologs within AD CNV regions are strikingly refractory to CNVs. Dosage Sensitive Genes Causing Alzheimer's Disease . doi:10.1093/molbev/msx183 MBE Next, we investigated the proportion of ohnologs in all AD CNV genes. The proportion of ohnologs for AD CNV genes was 42% (208/497), while that for genes not including AD CNV genes in control CNVs was 33% (4,604/13,962). We observed a significant difference in the proportion between them (P ¼ 3:91 Â10 À5 ; v 2 test). We also observed that the proportion of nonCNV genes was 39% (192/497) out of the AD CNV genes while that for the other human genes was 29% (5,456/19,418) , which were significantly different (P ¼ 2:94 Â10 À7 ; v 2 test). These results also indicated that AD CNV regions contained ohnologs and nonCNV genes more frequently than control CNV regions. Thus, we found that AD CNV regions often contained dosage-sensitive genes whose dose changes were deleterious. This suggested that our approach using ohnologs for estimating causative genes in AD CNV regions is effective.
Dosage-Sensitive Genes in Previously Reported AD Causative Candidates
We attempted to identify the causative genes from multiple genes in the deleterious CNVs. From the aforementioned results 105 dosage-sensitive genes, which were ohnologs and nonCNV genes, were screened out of 497 AD CNV genes. We defined them as "AD CNV dosagesensitive genes (AD DSGs)." For identifying the candidate genes, we focused on gene knockout phenotypes and expression levels in various tissues. The deleterious phenotypes in mouse and the expression levels were used to screen the causative genes for diseases in some studies (Webber et al. 2009; Zahnleiter et al. 2013; An et al. 2016) . In this study, to identify the genes that were more likely to contribute to AD onset from AD CNV DSGs precisely, we first investigated the phenotypes in mouse and the expression levels of genes that have been already reported as causing AD. Dosage balance plays a key role in AD and stoichiometry constraints are effective for some causative genes within protein complexes or biological pathway (Veitia 2002; Birchler and Veitia 2012; McLysaght et al. 2014) . Hence, we selected 28 dosage-sensitive genes, which were ohnolog and nonCNV genes, from AD causative genes in Online Mendelian Inheritance in Man (OMIM), Alzgene, and five review articles (Bertram and Tanzi 2008; Khanahmadi et al. 2015; Giri et al. 2016; Rosenberg et al. 2016; Shen and Jia 2016) , and defined them "known AD DSGs" (supplementary table S2, Supplementary Material online).
"Nervous System" Is Enriched in Dosage-Sensitive AD CNV Genes
We used Mouse Genome Informatics (MGI) database, which exhibits associations between genotype and disease phenotype at the organismal level, following the disruption of mouse genes (Webber 2011) . It was demonstrated that the database provides plausible insights for human phenotypes as the outcome of structural variations of the genes (Webber et al. 2009 ) and the molecular and cellular pathogenesis of diseases (Shaikh et al. 2011) . It has also been reported that many mammalian phenotype ontology (MPO) in MGI are comparable to their associated human symptoms (Boulding and Webber 2012) . We obtained 29 categorized mammalian phenotype terms (MP terms), which represented a phenotype when a gene was knocked out or mutated. Of note, only 9,007 genes had MP terms in MGI. We inferred that MP terms for genes with important roles resulting in strong phenotypes in the knockout mouse would have been preferentially reported (Makino et al. 2009 ). To confirm this, we compared the proportion of the genes having at least 1 MP term for ohnologs with that for nonohnologs and found a significant difference between them (ohnologs; 61%, 4,458 out of 7,265; nonohnologs; 40%, 4,549 out of 12,650; P < 2:2Â10 À16 ; v 2 test). We also observed that nonCNV genes significantly had frequent MP terms (51%, 2,890 out of 5,694) than CNV genes (43%, 6,117 out of 14,266; P < 2:2Â10 À16 ; v 2 test). These results indicate that ohnologs and nonCNV genes are likely to be annotated MP terms because of their importance or pathogenicity. It is important to note that not having MP term does not indicate that the gene was not important; instead, we did not investigate it and excluded the genes without MP term.
First, we examined the enrichment of MP term in known AD DSGs and found that only the term "nervous system" term was enriched (P ¼ 0.014; supplementary table S3, Supplementary Material online). Then, we investigated whether the term "nervous system" was enriched in two gene groups in AD CNVs, AD CNV DSGs, and AD CNV nonDSGs. We observed that the term was enriched in AD CNV DSGs (P ¼ 0.0015; supplementary table S4, Supplementary Material online) but not in AD CNV nonDSGs (P ¼ 0.097; supplementary table S5, Supplementary Material online). In addition, we found that the proportion of genes that had the term "nervous system" was significantly higher in AD CNV DSGs than all ohnologs not including AD CNV genes and known AD DSGs (AD CNV DSGs; 60%; 41 out of 68; all ohnologs not including AD CNV MBE genes and known AD DSGs; 41%; 1,787 out of 4,369; P ¼ 1:2Â10 À7 ; fisher's exact test). It indicates that "nervous system" was condensed to AD CNV DSGs from all ohnologs. These results showed that AD CNV DSGs are more likely to relate to AD pathogenesis than AD CNV nonDSGs. Furthermore, it suggests that selecting dosage-sensitive genes out of all AD CNV genes is effective for estimating the causative genes. Here, we narrowed down the candidates down to 41 genes that had the term "nervous system" from 105 AD CNV DSGs with mouse deleterious phenotypes.
Dosage-Sensitive AD CNV Genes Expressed Highly in the Brain
We compared the expression levels among in the four groups, known AD DSGs, AD CNV DSGs, AD CNV nonDSGs, and the other protein-coding genes. We used the GTEx portal database, which was generated using RNA-seq with 53 tissues, and extracted the data of the median RPKM (Reads Per Kilobase of exon Model per million mapped reads) values by tissue for protein-coding genes. We classified the tissues into 31 major groups, calculated the mean RPKM for known AD DSGs and the other genes, and compared the ratio of the mean expression levels in the known AD dosage-sensitive genes to that in the other genes. We observed that the brain had the highest ratio among tissues used in this study (supplementary fig. S1 , Supplementary Material online). This indicates that high expression levels in the brain might have an important role in AD pathogenesis.
Thus, we compared the proportion of genes that express in the brain but not in any other tissue, defined "brain-specific genes." We excluded the genes absent in the GTEx portal. Two out of 28 (7.0%) in known AD DSGs, 3 out of 103 (2.9%) in AD CNV DSGs, 6 out of 377 genes (1.6%) in AD CNV nonDSGs, and 220 out of 18,192 (1.2%) in the other genes were brain-specific genes. Known AD DSGs had a high proportion of brain-specific genes, and AD CNV DSGs also tended to be brain-specific. Similar to the condensing of the term "nervous system", brain-specific genes were also condensed to AD CNV DSGs from all ohnologs not including AD CNV genes and known AD DSGs (AD CNV DSGs; 2.9%; 3 out of 103; all ohnologs not including AD CNV genes and known AD DSGs; 2.1%; 145 out of 6,939). In addition, we calculated the ratio of the expression levels in the brain to that in the other tissues for all genes in the four groups. Of note, we excluded the brain-specific genes to avoid illegal division although there were not many brain-specific genes. We observed that the ratio for known AD DSGs was higher than that of other genes (P ¼ 0.0012, Mann-Whitney U test) ( fig. 1 ). Similar to known AD DSGs, the expression of AD CNV DSGs was higher in the brain than in the other tissues compared to other genes (P ¼ 0.0019, Mann-Whitney U test; fig.  1 ). In contrast, there was no difference between the ratio between AD CNV nonDSGs and other genes (P ¼ 0.75; Mann-Whitney U test; fig. 1 ). Furthermore, there was a significant difference in the ratio between AD CNV DSGs and AD CNV nonDSGs (P ¼ 0.0032, Mann-Whitney U test) and between AD CNV DSGs and all ohnologs not including AD CNV genes and known AD DSGs (P ¼ 0.020, Mann-Whitney U test; fig. 1 ). These results indicate that AD CNV DSGs were highly expressed in the brain similar to the known AD DSGs. We did not observe this trend for AD CNV nonDSGs. Thus, it was suggested that AD CNV DSGs are more likely to contribute to AD pathogenesis than AD CNV nonDSGs. We obtained 46 genes with the expression ratio (brain/other tissues) > 1 or brain-specific expression from 105 AD CNV DSGs.
Validation for Other Pathogenic CNVs
To validate our approach, we investigated knockout phenotypes and expression ratios (brain/other tissues) for other pathogenic CNVs specific to patients with intellectual disability (ID) and related developmental disorders (Cooper et al. 2011) . Pathogenic CNVs were identified by comparison of 15,767 patients and 8,329 controls (Cooper et al. 2011 
Discussion
Recent studies showed the possibility to predict diseasecausing genes from the aspect of dosage sensitivity (Makino and McLysaght 2010; McLysaght et al. 2014) . In this study, we demonstrated that the evolutionary feature of ohnologs is helpful to identify disease-causing genes in pathogenic CNV regions. Although the previous study showed the relationship between ohnologs and neurodevelopmental diseases (McLysaght et al. 2014 ), true disease-causing genes were still hidden in multiple genes in pathogenic CNV regions. In this study, we selected the genes based on dosage sensitivity, phenotypes of knockout mouse, and expression levels in tissues. Finally, we integrated our results, and then selected 21 AD candidate genes (table 2) .
Importantly, we revealed that AD CNV regions contained ohnologs and nonCNV genes frequently. This result supports previous observations that CNVs overlapping with ohnologs are deleterious and suggests a strong relationship between dosage sensitivity and AD (Makino and McLysaght 2010; Dosage Sensitive Genes Causing Alzheimer's Disease . doi:10.1093/molbev/msx183 MBE Makino et al. 2013; McLysaght et al. 2014 ). In addition, we found the enrichment of the term "nervous system" in mouse knockout phenotypes not only for known AD DSGs but also for AD CNV DSGs. These results are plausible because, as we mentioned in the Introduction, disorders with neuropsychiatric symptoms are related to CNVs. Furthermore, it has been suggested that "nervous system" is associated with copy number alterations that result in neurodevelopmental or neurodegenerative diseases (Lee and Lupski 2006) .
We also revealed that the expression in the brain was important in AD pathogenesis as both the expression levels in the brain and the proportion of brain-specific genes were significantly higher in known AD DSGs and AD CNV DGSs than in control genes. Although there was no significant difference in the proportion of brain-specific genes between AD CNV DSGs and AD CNV nonDSGs owing to lack of statistical power, we found dissimilarity in the expression level in the brain between them ( fig. 1) . These results were also in line with those of a report that showed that the expression of CNV genes in the brain is more strictly regulated than in other tissues, and the dosage balance is more important in the brain ). Owing to high dosage sensitivity in the brain, neurodevelopmental or neurodegenerative disorders associated with the brain might also be strongly associated with CNVs.
We successfully demonstrated that our approach could be applied to not only AD CNVs, but also other pathogenic CNVs. Both the results of mouse knockout phenotypes and expression pattern in human tissues for genes in AD CNV regions indicated that screening dosage-sensitive genes might be useful in identifying the causative genes for AD. We identified 21 dosage-sensitive genes that had the term "nervous system" and highly expressed in the brain as AD candidate genes (table 2). In the final candidate genes, there were two known AD DSGs, APP and ATXN1, which we have described in the Introduction, and this fact indicates that our approach worked efficiently. Our candidate genes are likely to have a role in neurons or synapses, and association with AD and other neurodevelopmental or neurodegenerative disorders owing to the harmfulness of their CNVs and other mutations (table 2) . Interestingly, it has been reported that not only AD but also other neurodevelopmental disorders were caused by CNVs including the candidate genes (Matilla et al. 1998; Prasher et al. 1998; Yue et al. 2005; Rovelet-Lecrux et al. 2006; Sleegers et al. 2006; Kim et al. 2008; Marshall et al. 2008; Ching et al. 2010; Crespo-Barreto et al. 2010; Bremer et al. 2011; Van Daalen et al. 2011; Greenwood et al. 2012; McNaughton et al. 2012; Celestino-Soper et al. 2012; Campbell et al. 2013; Ripke et al. 2014; Vergult et al. 2014; Bushman et al. 2015; Jang et al. 2015; Uehara et al. 2015; Nicita et al. 2016 ). In addition, nonCNV mutations such as single nucleotide mutation in the candidate genes also cause the neurodevelopmental disorders (Goate et al. 1991; Mullan et al. 1992; Mattson 2000; Shimohama 2000; Sisodia and St George-Hyslop 2002; Choudary et al. 2005; Hannula-Jouppi et al. 2005; Law et al. 2007; Potkin et al. 2009; Zoghbi and Orr 2009; Bettens et al. 2010; Biffi et al. 2010; Cherlyn et al. 2010; Fukata et al. 2010; Zucker et al. 2010; Yue et al. 2011; Casey et al. 2012; Jia et al. 2012; Liu et al. 2012; Gusareva et al. 2014; Kaalund et al. 2014; Namjou et al. 2014; Dazzo et al. 2016; Hondius et al. 2016) . For example, mutations of ERBB4 relating to spine density or area and synaptic transmission (Li et al. 2007 ) has connections with many neuronal disorders, including AD, autism spectrum, and schizophrenia (Sisodia and St George-Hyslop 2002; Bremer et al. 2011; Greenwood et al. 2012 ). Furthermore, ROBO1, which is important for neuronal axon guidance is associated with dyslexia and epilepsy ( fig. 2 ; Hannula-Jouppi et al. 2005; Kaalund et al. 2014 ). This also suggests that the investigation of the relationship between AD and its suspected disorders such as autism spectrum and schizophrenia might help in understanding the contribution of CNVs to pathogenesis. Further research on CNVs in patients with AD is needed for genes such as ATXN1, CNTN5, and MAGI2 that have reported associations with AD caused by other mutations such as single nucleotide mutations ( fig. 2) . Although BHLHE22 (BHLHB5) has not been reported to have any relationship with any neuropsychiatric disorders, this gene has important functions in the brain. BHLHE22 is a basic helix-loop-helix (bHLH) transcription 
Dosage Sensitive Genes Causing Alzheimer's Disease . doi:10.1093/molbev/msx183 MBE factor expressed in the layers of the neocortex and is a postmitotic regulator of area identity during development ( fig. 2 ; Joshi et al. 2008) . We found several bHLH transcription factor ohnologs within AD CNV regions (NEUROD1, MYOD1, MYF5, and MYF6), although these do not express highly in the brain or exhibit knockout phenotypes related to the nervous system. BHLHE22 negatively regulates NEUROD1 (BHLHA3) and MYOD1 (bHLHc1) responsive genes involved in neuronal differentiation (Peyton et al. 1996) . MYF5 (bHLHc2) has overlapping roles for MYOD1 modulation (Ishibashi et al. 2005) , and has a paralog, MYF6 (bHLHc4), clustered on chromosome 12. Furthermore, deletion of the zinc finger transcription factor TSHZ3 causes autism syndrome with accompanying up-regulation of BHLHE22 and ELMOD1 ( fig. 2 and table 2 ), although TSHZ3 is not located in AD CNVs (Caubit et al. 2016) . Recently, it was reported that TSHZ3 is associated with AD (Louwersheimer et al. 2017) . Transcription factors are likely to be dosage-sensitive genes, and their dosage imbalance would influence dosage of their target genes, resulting in human diseases (Veitia 2002; Makino and McLysaght 2010; Birchler and Veitia 2012) . Neural bHLH transcription factors such as BHLHE22, active in neocortex development, would be strong candidates for AD-causing genes. LRRTM4 is important for synaptogenic activity in brain, and its deletion in the dentate gyrus granule cells causes reduction in the excitatory synapse density and function in mice ( fig. 2 ; Siddiqui et al. 2013) . Thus, LRRTM4 might be associated with AD pathogenesis in some regions. The estimation of a few causative genes is feasible even amongst multiple genes within long AD CNV regions. Although one AD CNV region (chromosome 7: 78,325,192-89,993,005) contains five candidate genes, we successfully reduce the number of candidate genes out of multiple genes within pathogenic CNV regions ( fig. 2 ). This candidate gene list (table 2) is useful for furthering CNV research on AD in the laboratory and putting the knowledge to clinical use. As a limitation of this study, we might have eliminated true disease-causing genes because some nonohnologs are also dosage-sensitive. Another issue is that the completeness of mouse genes with MP term in MGI is not high. When the number of genes with MP term in the database would increase, the quality and quantity of AD candidate genes would subsequently improve. In addition, further experiments with neuronal activity are required to investigate the dosage sensitivity and pathogenicity of our candidate genes.
In conclusion, we demonstrated that our novel methodology based on the evolutionary feature of genes might be useful to identify the causative genes in pathogenic CNV regions for diseases caused by dosage imbalance. It might enable us to investigate the contribution of CNVs to various diseases and help medical diagnosis in future.
Materials and Methods
Human Genes and Genome
We obtained gene locations for a human genome (hg38) from Ensemble release 85 (http://www.ensembl.org/index. html). We used 19,915 protein-coding genes. 
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Ohnologs
We downloaded protein sequences for human, zebrafish (Danio rerio), tetraodon (Tetraodon nigroviridis), stickleback (Gasterosteus aculeatus), medaka (Oryzias latipes), fugu (Takifugu rubripes), and an outgroup, which was ascidian (Ciona intestinalis), from Ensembl release 85, and obtained human ohnologs identified by a method described in a previous report (Makino and McLysaght 2010) . We also used 1 of 5 outgroups, which were amphioxus (Branchiostoma floridae) v1.0 from JGI (http://www.jgi.doe.gov), sea urchin (Strongylocentrotus purpuratus) release 101 from NCBI (http://www.ncbi.nlm.nih.gov), another ascidian (Ciona savignyi), fly (Drosophila melanogaster), and worm (Caenorhabditis elegans) from Ensembl release 85 instead of C. intestinalis for identifying ohnologs, then combined their ohnolog data sets.
Genes Overlapping with CNVs in Patients with AD
We obtained the locations of pathogenic CNVs from ten reports in patients with AD/MCI (Shaw et al. 2011; Swaminathan et al. 2011; Ghani et al. 2012; Hoo Li et al. 2012 ; we did not distinguish between early-onset AD and late-onset AD in this study and excluded duplicate of CNVs overlapping with the same gene set. The AD CNVs were detected by some of the major approaches, including array CGH (Shaw et al. 2011 ; Rovelet-Lecrux A), Affymetrix Genome-Wide Human SNP Array 6.0 (Hoo Swaminathan et al. 2012a; Szigeti et al. 2013 Szigeti et al. , 2014 , Human-610 Quad BeadChip (Guffanti et al. 2013; Swaminathan et al. 2011 Swaminathan et al. , 2012b and Illumina HumanHap 650Y array (Ghani et al. 2012) . We obtained 61 CNV regions that were observed significantly in patients compared to controls through statistical analysis. The extent of AD CNVs ranges from 15 kb to 16 Mb (supplementary table S1, Supplementary Material online). We added APP duplication, established as causative CNV for AD, and two novel CNVs overlapping with ERBB4 ( fig. 2) or NRXN1, which are often reported in patients and suspected to contribute to AD strongly (Swaminathan et al. 2011 (Swaminathan et al. , 2012b 
Genes with Copy Number Variations
We retrieved CNVs from healthy control samples in human from Database of Genomic Variants GRCh38 version (http:// dgv.tcag.ca/dgv/app/home). When the entire coding sequence of a gene was within 1 of the copy number variants, we defined the gene as a CNV gene. We used 24,034 CNVs containing protein-coding genes, and classified human genes into 14,266 CNV genes and 5,694 nonCNV genes.
Genes Associated with AD
We obtained 96 genes that have been reported to have an association with AD from morbidmap.txt as a susceptible gene, in Online Mendelian Inheritance in Man (OMIM) (https://omim.org/downloads/), top ten results of AlzGene (http://www.alzgene.org/), and five review articles (Bertram and Tanzi 2008; Khanahmadi et al. 2015; Giri et al. 2016; Rosenberg et al. 2016; Shen and Jia 2016) (supplementary  table S2 , Supplementary Material online). These genes might cause AD by different mechanisms from dosage imbalance. Therefore, we selected 28 dosage-sensitive genes, which were ohnologs and nonCNV genes that have never been reported in DGV database, and used them as the known AD dosagesensitive genes.
Genes Associated with Intellectual Disability and Related Developmental Disorders
Pathogenic CNVs causing intellectual disability (ID) and related developmental disorders were identified by comparison of 15,767 patients and 8,329 controls (Cooper et al. 2011) . We used 351 genes in the pathogenic CNVs (Cooper et al. 2011 ) from a supplementary table in the report by McLysaght et al. (2014) . We classified the genes into 73 ID CNV DSGs (supplementary table S6, Supplementary Material online) and 278 ID CNV nonDSGs. We used known genes causing ID and related developmental disorders as reported by Vissers et al. (2016) , and obtained 17 identified ID DSGs from the characterized ID causing genes (supplementary table S7, Supplementary Material online).
Genes and Mammalian Phenotype Annotations
We obtained genes and Mammalian phenotype id (MP id) from Mouse Genome Informatics (MGI) (http://www.inform atics.jax.org/) and downloaded Mouse/Human Orthology with Phenotype Annotations and Mammalian Phenotype Vocabulary. We calculated the P value for each MP id by comparison of the observed frequency of known AD dosage-sensitive genes, dosage-sensitive AD genes, or nondosage-sensitive AD CNV genes with expectations based on the hypergeometric distribution using all genes with at least 1 MP id. The estimated P values were adjusted by BenjaminiHochberg correction.
Genes and Expression Levels in Tissues
We obtained the gene expression data from the GTEx portal (http://www.gtexportal.org/home/). We downloaded the file of the median RPKM by tissue. We excluded the RPKM values that were <1 as not being expressed accounting for fluctuation. There were 53 tissues categorized to 31 major tissues (the adipose, adrenal gland, artery, bladder, brain, breast, cells, cervix, colon, esophagus, fallopian tube, heart, kidney, liver, lung, minor salivary gland, muscle, nerve, ovary, pancreas, pituitary, prostate, skin, small, spleen, stomach, testis, thyroid, uterus, vagina, and whole blood). They contained 13 tissues grouped into the brain and 40 tissues grouped into the other 30 major tissues based on the GTEx category. We calculated the mean expression levels for each major tissue. We defined genes that were expressed in the brain but not in any other major tissue as "brain-specific genes." We calculated the ratio of the mean of the expression levels in the brain to that in the other tissues and excluded brain-specific genes to avoid illegal division. Moreover, we corrected P values with BenjaminiHochberg correction.
Supplementary Material
Supplementary data are available at Molecular Biology and Evolution online.
